Business
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial CAMBRIDGE,
About this update from Nuvalent, Inc.
[{"type":"text","content":"Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 Phase 1/2 clinical trial, in addition to preliminary data for TKI-naïve patients, will be presented during an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago. \n \n \n \n \n \n \n \nAdditionally, preliminary data in patients with advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 Phase 1/2 clinical trial of zidesamtinib, an investigational ROS1-selective inhibitor, will be presented during a poster session.Details of the presentations are as follows:Title: ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLCPresenting Author: Jessica J. Lin, M.D.1Abstract Number: 8503Oral Session Title: Lung Cancer—Non-Small Cell MetastaticPresentation Date and Time: May 29, 2026, 1:00 PM-4:00 PM CDTLocation: Hall D2 Title: Zidesamtinib efficacy and safety in patients with advanced ROS1-positive solid tumors other than NSCLC in the ARROS-1 study Presenting Author: Benjamin Solomon, M.D., Ph.D.2Abstract Number: 3108Poster Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologySession Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT Location: Hall APoster Board Number: 2451 Mass General Brigham Cancer Institute, Boston, MA, USA; 2 Peter MacCallum Cancer Centre, Melbourne, Australia About NeladalkibNeladalkib is an investigational, brain-penetrant, ALK-selective inhibitor created with the aim to overcome limitations observed with currently available ALK inhibitors. Neladalkib is designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with single or compound treatment-emergent ALK mutations such as G1202R. In addition, neladalkib is designe...